Prasad Raju 4
4 · CRISPR Therapeutics AG · Filed Oct 3, 2025
Insider Transaction Report
Form 4
Prasad Raju
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2025-10-03+16,500→ 16,500 totalExercise: $67.74Exp: 2035-10-03→ Common Shares (16,500 underlying)
Footnotes (1)
- [F1]This option was granted on October 3, 2025 with respect to 16,500 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 3, 2025.